Press Releases

As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs and the Early Access to Medicines Scheme was introduced. Key implementation of this will be a factor into further...

Provence Technologies acquires SynprosisThe acquisition strengthens Provence Technologies’ expertise in its core business of therapeutic chemistryProvence Technologies Group, a specialist fine chemistry research group, today announces its acquisition of Synprosis, a company specialized in the chemical synthesis of peptides...

Disruptive Innovation – Health – Funding | Immunotherapies – Healthy AgeingOnly one week left to join us in Lyon to meet the key international players in health care and life sciences, including representatives from academia, the public and private...

The Orphan Drugs Market is set to Rise as a Result of Pharma Companies now Looking to Orphan Drugs as an Essential Revenue Stream in 2014   As of January 2014, the EMA lifted the restriction...

Bionetworks: reviewing the various collaborations between pharma, biotech, academia and venture capitalists As many pharmaceutical companies’ needs for growing their pipelines rise, this is fuelling the increase in partnerships with external groups – academia, biotech and funding organisations._______________________________ Companies are...

Polyplus-transfection SA, a privately-held company specializing in the development of innovative solutions for transfection, today announces the launch of FectoPRO(TM), the latest optimised transfection reagent in their product portfolio. FectoPRO has been designed for high yields in medium and...

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the nomination of Dr Youssef L. Bennani to the board of directors. Following this nomination, Youssef L....